TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00680095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 Solution, 2.5%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 Solution, 7.5%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 Solution, 5.0%, Daily for up to 21 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AN2690 Solution, Vehicle
Description: AN2690 Solution, Vehicle, Daily for up to 21 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lauryl Sulfate, 0.5%
Description: Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Study: NCT03247985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROLENE Polypropylene Tacking Mesh
Description: Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGrip Self-fixating Mesh
Description: ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation
Study: NCT01204775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saxagliptin)
Description: Tablets, Oral, Once daily, 1-16 weeks
Study: NCT04711590

Intervention type: OTHER
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (dark blue)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study: NCT01854190

Intervention type: DEVICE
Intervention: WatchPAT
Description: BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.

Intervention type: DEVICE
Intervention: WatchPAT
Description: BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
Study: NCT03227289

Intervention type: OTHER
Intervention: Stayed in NRDS
Description: The neonates with NRDS are stayed in NRDS.
Study: NCT03801733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose of 600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose of 600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose of 600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Oral Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Oral Pravastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Oral Sulfasalazine
Study: NCT02260492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT329 (combination of fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (lactose) administered via the Solis dry powder inhaler
Study: NCT02402868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine and saline
Description: Ketamine intravenous and intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and saline
Description: Ketamine intravenous and intranasal
Study: NCT01898910

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI+renal denervation
Description: After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + GP ablation
Description: To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medial therapy (OMT)
Description: Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medial therapy (OMT)
Description: Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
Study: NCT02542124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12 and TSEBT
Description: The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
Study: NCT02022501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120
Study: NCT03227289

Intervention type: OTHER
Intervention: Converted to ARDS
Description: The neonates with NRDS are converted to ARDS.
Study: NCT01063738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplement
Description: Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplement
Description: Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEPSE
Description: Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEPSE
Description: Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package
Study: NCT02022501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120
Study: NCT01063738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nutritional supplement
Description: Cherry flavoured low calorie and low protein placebo drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo nutritional supplement
Description: Cherry flavoured low calorie and low protein placebo drink
Study: NCT02564653

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Technical Assistance, training and clinical reminders
Description: Technical Assistance, training and clinical reminders (TTC)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TTC+Referral to Community Health Worker
Description: TTC+ referral to a VHW for additional counseling and follow-up
Study: NCT02986022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience
Description: Self-efficacy, optimism, altruism, goal setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience
Description: Self-efficacy, optimism, altruism, goal setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
Study: NCT02897102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training program based on abacus and other activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different group activities
Description: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
Study: NCT01275365

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone enanthate
Description: Testosterone enanthate 100 mg intramuscularly weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone enanthate
Description: Testosterone enanthate 100 mg intramuscularly weekly
Study: NCT05429801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
Study: NCT02684097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tralokinumab
Description: All groups will receive study drug every two weeks for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given every two weeks for 24 weeks
Study: NCT02464332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Description: All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.
Study: NCT01317095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternalock Rigid Fixation
Description: Patients will have their sternum closed by rigid fixation using Sternalock plates.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternalock Rigid Fixation
Description: Patients will have their sternum closed by rigid fixation using Sternalock plates.
Study: NCT01839890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal Stent plus Paclitaxel Balloon
Description: After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal Stent
Description: After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
Study: NCT00931528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
Study: NCT02354677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro experiments on bronchial epithelial cells
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mylife
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeriFine
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdot
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study: NCT00381862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: as per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: as per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: as per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: as per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Palonosetron 0.25 mg IV push on day 1 only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: baseline
Study: NCT03813680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Vertebral Mobilization
Description: Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF exercise
Description: The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
Study: NCT01545531

Intervention type: DRUG
Intervention: Iohexol
Description: Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
Study: NCT02007681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of sedentary time by breaking it with low intensity physical activity
Description: One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
Study: NCT02464592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial lung biopsy.
Description: Transbronchial lung biopsy with cryoprobe and with conventional forceps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial lung biopsy.
Description: Transbronchial lung biopsy with cryoprobe and with conventional forceps.
Study: NCT00791778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
Study: NCT02689193

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
Study: NCT04522401

Intervention type: DIAGNOSTIC_TEST
Intervention: consultation: Bien vieillir
Description: Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
Study: NCT02813850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: Oxygen therapy early in the night (2L/min) during 4hours per days
Study: NCT02475096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
Study: NCT05440526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst Group
Description: Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFBC Group
Description: TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.